Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, rifamycin sodium (Relafalk®) cannot be endorsed for use within NHS Wales for the treatment of traveller’s diarrhoea in adults accompanied by symptoms like nausea, vomiting, gas/flatulence, rectal tenesmus, faecal urgency and abdominal pain or cramps without clinical signs of invasive enteritis such as fever, blood, occult blood or leucocytes in the stools. This product is currently not marketed in the UK. |
||
|
||
Medicine details |
||
| Medicine name | rifamycin sodium (Relafalk®) | |
| Formulation | 200 mg modified-release tablet | |
| Reference number | 2034 | |
| Indication | For the treatment of traveller’s diarrhoea in adults accompanied by symptoms like nausea, vomiting, gas/flatulence, rectal tenesmus, faecal urgency and abdominal pain or cramps without clinical signs of invasive enteritis such as fever, blood, occult blood or leucocytes in the stools |
|
| Company | Dr Falk Pharma UK Ltd | |
| BNF chapter | Gastro-intestinal system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 16/06/2020 | |
| Further information This product is currently not marketed in the UK. |
||